Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials - Concepedia

Concepedia

Publication | Open Access

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

DOI Full Paper Access

47

Citations

9

References

2020

Year

Jean van Wyk, Chloe Orkin, Rafael Rubio, Johannes R. Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley Kahl, Jessica Matthews,

JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

Switching to the 2-drug regimen dolutegravir plus rilpivirine maintained virologic suppression for a high proportion of participants through 3 years, with low rates of virologic failure and a well-tolerated safety profile.

References

	Year	Citations

Page 1